Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge is the side effect of bleeding. Improved understanding of the mechanisms of haemostasis and thrombosis has revealed new targets for attenuating thrombosis with the potential for less bleeding, including glycoprotein VI on platelets and factor XIa of the coagulation system. The efficacy and safety of new agents are currently being evaluated in phase III trials. This Review provides an overview of haemostasis and thrombosis, details the current landscape of antithrombotic agents, addresses challenges with preventing thromboembolic events in patients at high risk and describes the emerging therapeutic strategies that may break the inexorable link between antithrombotic therapy and bleeding risk.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis
Scientific Reports Open Access 13 June 2022
Signal Transduction and Targeted Therapy Open Access 10 March 2022
Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation
Nature Cardiovascular Research Open Access 10 February 2022
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wendelboe, A. M. & Raskob, G. E. Global burden of thrombosis: epidemiologic aspects. Circ. Res. 118, 1340–1347 (2016).
Prandoni, P. Venous and arterial thrombosis: two aspects of the same disease? Eur. J. Intern. Med. 20, 660–661 (2009).
Prandoni, P. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J. Thromb. Haemost. 4, 1891–1896 (2006).
Reich, L. M. et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J. Thromb. Haemost. 4, 1909–1913 (2006).
Braekkan, S. K. et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. J. Thromb. Haemost. 6, 1851–1857 (2008).
Bova, C. et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb. Haemost. 96, 132–136 (2006).
Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–918 (2008). The paper describes the mechanisms of arterial and venous thrombosis and targets for antithrombotics.
Previtali, E., Bucciarelli, P., Passamonti, S. M. & Martinelli, I. Risk factors for venous and arterial thrombosis. Blood Transfus. 9, 120–138 (2011).
Owens, A. P. III & Mackman, N. Role of tissue factor in atherothrombosis. Curr. Atheroscler. Rep. 14, 394–401 (2012).
Wolberg, A. S. et al. Venous thrombosis. Nat. Rev. Dis. Prim. 1, 15006 (2015).
Khan, A. A. & Lip, G. Y. H. The prothrombotic state in atrial fibrillation: pathophysiological and management implications. Cardiovasc. Res. 115, 31–45 (2019).
Watson, T., Shantsila, E. & Lip, G. Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 373, 155–166 (2009).
Medcalf, R. L. Fibrinolysis: from blood to the brain. J. Thromb. Haemost. 15, 2089–2098 (2017).
Lin, L. et al. Clinical and safety outcomes of oral antithrombotics for stroke prevention in atrial fibrillation: a systematic review and network meta-analysis. J. Am. Med. Dir. Assoc. 16, 1103.e1–19 (2015).
Doktorova, M. & Motovska, Z. Clinical review: bleeding–a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management. Crit. Care 17, 239 (2013).
Marzec, L. N. et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J. Am. Coll. Cardiol. 69, 2475–2484 (2017).
Plow, E. F., Wang, Y. & Simon, D. I. The search for new antithrombotic mechanisms and therapies that may spare hemostasis. Blood 131, 1899–1902 (2018).
Grover, S. P., Bergmeier, W. & Mackman, N. Platelet signaling pathways and new inhibitors. Arterioscler. Thromb. Vasc. Biol. 38, e28–e35 (2018).
Fredenburgh, J. C., Gross, P. L. & Weitz, J. I. Emerging anticoagulant strategies. Blood 129, 147–154 (2017).
McFadyen, J. D., Schaff, M. & Peter, K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat. Rev. Cardiol. 15, 181–191 (2018). The paper summarizes antiplatelet trials in patients with cardiovascular disease and new antiplatelet agents.
Grover, S. P. & Mackman, N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler. Thromb. Vasc. Biol. 38, 709–725 (2018).
Gremmel, T., Frelinger, A. L. III & Michelson, A. D. Platelet physiology. Semin. Thromb. Hemost. 42, 191–204 (2016).
Ten Cate, H., Hackeng, T. M. & Garcia de Frutos, P. Coagulation factor and protease pathways in thrombosis and cardiovascular disease. Thromb. Haemost. 117, 1265–1271 (2017). The paper describes the coagulation protease cascade and its role in thrombosis, thrombo-inflammation and atherosclerosis.
Broos, K., Feys, H. B., De Meyer, S. F., Vanhoorelbeke, K. & Deckmyn, H. Platelets at work in primary hemostasis. Blood Rev. 25, 155–167 (2011).
Stalker, T. J., Welsh, J. D. & Brass, L. F. Shaping the platelet response to vascular injury. Curr. Opin. Hematol. 21, 410–417 (2014).
Stegner, D. & Nieswandt, B. Platelet receptor signaling in thrombus formation. J. Mol. Med. 89, 109–121 (2011).
Bergmeier, W. & Stefanini, L. Platelets at the vascular interface. Res. Pract. Thromb. Haemost. 2, 27–33 (2018).
Esmon, C. T. Regulation of blood coagulation. Biochim. Biophys. Acta 1477, 349–360 (2000).
Esmon, C. T. The endothelial cell protein C receptor. Thromb. Haemost. 83, 639–643 (2000).
Mackman, N. Tissue-specific hemostasis in mice. Arterioscler. Thromb. Vasc. Biol. 25, 2273–2281 (2005).
Rosenberg, R. D. & Aird, W. C. Vascular-bed-specific hemostasis and hypercoagulable states. N. Engl. J. Med. 340, 1555–1564 (1999).
Stefanini, L. & Bergmeier, W. Negative regulators of platelet activation and adhesion. J. Thromb. Haemost. 16, 220–230 (2018).
Robson, S. C. et al. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin. Thromb. Hemost. 31, 217–233 (2005).
Wood, J. P., Ellery, P. E., Maroney, S. A. & Mast, A. E. Biology of tissue factor pathway inhibitor. Blood 123, 2934–2943 (2014).
Rosenberg, R. D. & Rosenberg, J. S. Natural anticoagulant mechanisms. J. Clin. Invest. 74, 1–6 (1984). Overview of how anticoagulant mechanisms balance procoagulants in different vascular beds.
Bryckaert, M., Rosa, J. P., Denis, C. V. & Lenting, P. J. Of von Willebrand factor and platelets. Cell Mol. Life Sci. 72, 307–326 (2015).
Nieswandt, B. & Watson, S. P. Platelet-collagen interaction: is GPVI the central receptor? Blood 102, 449–461 (2003). The paper describes the role of platelet GPVI in haemostasis and arterial thrombosis.
Stefanini, L. & Bergmeier, W. RAP GTPases and platelet integrin signaling. Platelets 30, 41–47 (2019).
Shattil, S. J. & Newman, P. J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104, 1606–1615 (2004).
Huang, Y. et al. Arf6 controls platelet spreading and clot retraction via integrin αIIbβ3 trafficking. Blood 127, 1459–1467 (2016).
Drake, T. A., Morrissey, J. H. & Edgington, T. S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am. J. Pathol. 134, 1087–1097 (1989).
Hoffman, M. et al. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J. Thromb. Haemost. 5, 1403–1408 (2007).
Hoffman, M. & Monroe, D. M. Tissue factor in brain is not saturated with factor VIIa: implications for factor VIIa dosing in intracerebral hemorrhage. Stroke 40, 2882–2884 (2009).
Gailani, D. & Renne, T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J. Thromb. Haemost. 5, 1106–1112 (2007). The paper provides an overview of the intrinsic pathway of coagulation and the potential for FXI and FXII as targets for new anticoagulants.
Puy, C., Rigg, R. A. & McCarty, O. J. The hemostatic role of factor XI. Thromb. Res. 141, S8–S11 (2016).
Lillicrap, D. The molecular pathology of hemophilia A. Transfus. Med. Rev. 5, 196–206 (1991).
Tjarnlund-Wolf, A. & Lassila, R. Phenotypic characterization of haemophilia B - Understanding the underlying biology of coagulation factor IX. Haemophilia 25, 567–574 (2019).
Bolton-Maggs, P. H. & Pasi, K. J. Haemophilias A and B. Lancet 361, 1801–1809 (2003).
Mann, K. G. Thrombin formation. Chest 124 (Suppl. 3), 4–10 (2003).
Loskutoff, D. J. & Curriden, S. A. The fibrinolytic system of the vessel wall and its role in the control of thrombosis. Ann. N. Y. Acad. Sci. 598, 238–247 (1990).
Wiman, B. & Collen, D. On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. J. Biol. Chem. 254, 9291–9297 (1979).
Johnson, G. J., Leis, L. A. & Bach, R. R. Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty. Thromb. Haemost. 102, 728–734 (2009).
Grover, S. P. & Mackman, N. Intrinsic pathway of coagulation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 39, 331–338 (2019).
Thalin, C., Hisada, Y., Lundstrom, S., Mackman, N. & Wallen, H. Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis. Arterioscler. Thromb. Vasc. Biol. 39, 1724–1738 (2019).
Martinod, K. & Wagner, D. D. Thrombosis: tangled up in NETs. Blood 123, 2768–2776 (2014).
Martinod, K. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc. Natl Acad. Sci. USA 110, 8674–8679 (2013).
Kokoye, Y. et al. A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. Thromb. Res. 140, 118–124 (2016).
Kuijpers, M. J. et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler. Thromb. Vasc. Biol. 34, 1674–1680 (2014).
van Montfoort, M. L. et al. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 34, 1668–1673 (2014).
Mackman, N. New targets for atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 34, 1607–1608 (2014).
Yau, J. W. et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123, 2102–2107 (2014). The paper shows that knockdown of either FXII or FXI but not FVII prolonged the time to catheter occlusion in a rabbit model.
Larsson, M. et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci. Transl. Med. 6, 222ra217 (2014). The paper shows that a FXII antibody inhibited thrombosis in an extracorporeal circuit as effectively as heparin without increasing bleeding in a rabbit model.
Vilahur, G., Ben-Aicha, S. & Badimon, L. New insights into the role of adipose tissue in thrombosis. Cardiovasc. Res. 113, 1046–1054 (2017).
Dellas, C. & Loskutoff, D. J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb. Haemost. 93, 631–640 (2005).
Huang, G., Wang, P., Li, T. & Deng, X. Genetic association between plasminogen activator inhibitor-1 rs1799889 polymorphism and venous thromboembolism: evidence from a comprehensive meta-analysis. Clin. Cardiol. 42, 1232–1238 (2019).
Patrono, C. et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J. Am. Coll. Cardiol. 70, 1760–1776 (2017).
Serebruany, V. L., Malinin, A. I., Eisert, R. M. & Sane, D. C. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am. J. Hematol. 75, 40–47 (2004).
Raimondi, P., Hylek, E. M. & Aronis, K. N. Reversal agents for oral antiplatelet and anticoagulant treatment during bleeding events: current strategies. Curr. Pharm. Des. 23, 1406–1423 (2017).
Nagalla, S. & Sarode, R. Role of platelet transfusion in the reversal of anti-platelet therapy. Transfus. Med. Rev. 33, 92–97 (2019).
Bhatt, D. L. et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N. Engl. J. Med. 380, 1825–1833 (2019).
Taylor, G., Osinski, D., Thevenin, A. & Devys, J. M. Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? J. Trauma. Acute Care Surg. 74, 1367–1369 (2013).
Baharoglu, M. I. et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 387, 2605–2613 (2016).
O’Donoghue, M. & Wiviott, S. D. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 114, e600–e606 (2006).
Angiolillo, D. J. et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol. 48, 298–304 (2006).
Dayoub, E. J. et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern. Med. 178, 943–950 (2018).
Paniccia, R., Priora, R., Liotta, A. A. & Abbate, R. Platelet function tests: a comparative review. Vasc. Health Risk Manag. 11, 133–148 (2015).
Aradi, D. et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int. J. Cardiol. 167, 2140–2148 (2013).
Hulot, J. S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244–2247 (2006).
Claassens, D. M. F. et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N. Engl. J. Med. 381, 1621–1631 (2019). The paper shows a benefit of using a CYP2C19 genotype-guided strategy for the selection of P2Y 12 inhibitor therapy.
McFadden, E. P. et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364, 1519–1521 (2004).
Levine, G. N. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 68, 1082–1115 (2016).
Collet, J. P. et al. Case-based implementation of the 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease. Eur. Heart J. 39, e1–e33 (2018).
Watanabe, H. et al. Very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. Circulation 140, 1957–1959 (2019).
Kuruvilla, M. & Gurk-Turner, C. A review of warfarin dosing and monitoring. Proceedings 14, 305–306 (2001).
Zhu, Y. et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53, 1199–1205 (2007).
Weitz, J. I., Jaffer, I. H. & Fredenburgh, J. C. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000Res 6, 985 (2017). The paper describes the benefits of direct oral anticoagulants over vitamin K antagonists for the treatment of venous thromboembolism.
Kearon, C. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149, 315–352 (2016).
Al-Samkari, H. & Connors, J. M. The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. Cancers 10, E271 (2018).
Levi, M. Management of bleeding in patients treated with direct oral anticoagulants. Crit. Care 20, 249 (2016).
Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G. & Lipman, M. L. Apixaban pharmacokinetics at steady state in hemodialysis patients. J. Am. Soc. Nephrol. 28, 2241–2248 (2017).
Eikelboom, J. W. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 369, 1206–1214 (2013). The trial comparing dabigatran with warfarin in patients with mechanical heart valves was stopped early owing to increased rates of thromboembolic and bleeding complications with dabigatran.
Pengo, V. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132, 1365–1371 (2018). The trial showed that the use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with increased rates of thrombosis compared with warfarin.
Leentjens, J., Peters, M., Esselink, A. C., Smulders, Y. & Kramers, C. Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs? Br. J. Clin. Pharmacol. 83, 2356–2366 (2017).
Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001–2015 (2007).
Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).
Tricoci, P. et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366, 20–33 (2012).
Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E. & Cook, J. R. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann. Intern. Med. 143, 241–250 (2005).
Alexander, J. H. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365, 699–708 (2011).
Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9–19 (2012). This trial shows that low-dose rivaroxaban reduced cardiovascular events in patients with a recent acute cardiovascular event treated with antiplatelet agents.
Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319–1330 (2017). The trial shows that the combination of low-dose rivaroxaban and aspirin reduced cardiovascular events in patients with stable atherosclerotic vascular disease compared with aspirin alone.
Connolly, S. J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391, 205–218 (2018).
Anand, S. S. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391, 219–229 (2018).
Lopes, R. D. et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol. 4, 747–755 (2019).
Yasuda, S. et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N. Engl. J. Med. 381, 1103–1113 (2019).
Powers, W. J. et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 49, e46–e110 (2018).
Gurwitz, J. H. et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann. Intern. Med. 129, 597–604 (1998).
Chatterjee, S. et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 311, 2414–2421 (2014).
Griffin, J. H., Zlokovic, B. V. & Mosnier, L. O. Activated protein C, protease activated receptor 1, and neuroprotection. Blood 132, 159–169 (2018). The paper describes the beneficial effects of an activated protein C variant in stroke.
Griffin, J. H., Mosnier, L. O., Fernandez, J. A. & Zlokovic, B. V. 2016 Scientific Sessions Sol Sherry distinguished lecturer in thrombosis: thrombotic stroke: neuroprotective therapy by recombinant-activated protein C. Arterioscler. Thromb. Vasc. Biol. 36, 2143–2151 (2016).
Mosnier, L. O., Zlokovic, B. V. & Griffin, J. H. Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thromb. Haemost. 112, 883–892 (2014).
Lyden, P. et al. Randomized, controlled, dose escalation trial of a protease-activated receptor-1 agonist in acute ischemic stroke: Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. Ann. Neurol. 85, 125–136 (2019).
Sharifi, M. et al. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am. J. Cardiol. 111, 273–277 (2013).
Sharifi, M. et al. Retrospective comparison of ultrasound facilitated catheter-directed thrombolysis and systemically administered half-dose thrombolysis in treatment of pulmonary embolism. Vasc. Med. 24, 103–109 (2019).
Piazza, G. et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc. Interv. 8, 1382–1392 (2015).
Nakanishi-Matsui, M. et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404, 609–613 (2000).
Nieman, M. T. Protease-activated receptors in hemostasis. Blood 128, 169–177 (2016).
Coughlin, S. R. Thrombin signalling and protease-activated receptors. Nature 407, 258–264 (2000).
Covic, L., Misra, M., Badar, J., Singh, C. & Kuliopulos, A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8, 1161–1165 (2002).
Kuliopulos, A. & Covic, L. Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis. Life Sci. 74, 255–262 (2003).
Gurbel, P. A. et al. Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 36, 189–197 (2016).
Aisiku, O. et al. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood 125, 1976–1985 (2015).
De Ceunynck, K. et al. PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury. Proc. Natl Acad. Sci. USA 115, E982–E991 (2018).
Wong, P. C. et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci. Transl. Med. 9, eaaf5294 (2017). Strong data in animal models supporting PAR4 as an antiplatelet target.
Wilson, S. J. et al. PAR4 (Protease-Activated Receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler. Thromb. Vasc. Biol. 38, 448–456 (2018).
French, S. L. et al. A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. Blood Adv. 2, 1283–1293 (2018).
Martins Lima, A., Martins Cavaco, A. C., Fraga-Silva, R. A., Eble, J. A. & Stergiopulos, N. From patients to platelets and back again: pharmacological approaches to glycoprotein VI, a thrilling antithrombotic target with minor bleeding risks. Thromb. Haemost. 119, 1720–1739 (2019).
Rayes, J., Watson, S. P. & Nieswandt, B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J. Clin. Invest. 129, 12–23 (2019).
Mammadova-Bach, E. et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood 126, 683–691 (2015).
Alshehri, O. M. et al. Fibrin activates GPVI in human and mouse platelets. Blood 126, 1601–1608 (2015).
Slater, A. et al. Does fibrin(ogen) bind to monomeric or dimeric GPVI, or not at all? Platelets 30, 281–289 (2019).
Onselaer, M. B. et al. Fibrin and D-dimer bind to monomeric GPVI. Blood Adv. 1, 1495–1504 (2017).
Ebrahim, M. et al. Dimeric glycoprotein VI binds to collagen but not to fibrin. Thromb. Haemost. 118, 351–361 (2018).
Induruwa, I. et al. Platelet collagen receptor glycoprotein VI-dimer recognizes fibrinogen and fibrin through their D-domains, contributing to platelet adhesion and activation during thrombus formation. J. Thromb. Haemost. 16, 389–404 (2018).
Schulz, C. et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic. Res. Cardiol. 103, 356–367 (2008).
Reininger, A. J. et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J. Am. Coll. Cardiol. 55, 1147–1158 (2010).
Kuijpers, M. J. et al. Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. J. Thromb. Haemost. 7, 152–161 (2009).
Nurden, A. T. Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein VI. Blood Rev. 38, 100592 (2019).
Arthur, J. F., Dunkley, S. & Andrews, R. K. Platelet glycoprotein VI-related clinical defects. Br. J. Haematol. 139, 363–372 (2007).
Gruner, S. et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 105, 1492–1499 (2005).
Reimann, A. et al. Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke. Heart Int. 11, e10–e16 (2016).
Ungerer, M. et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123, 1891–1899 (2011).
Schupke, S. et al. Revacept, a novel inhibitor of platelet adhesion, in patients undergoing elective PCI-Design and rationale of the randomized ISAR-PLASTER Trial. Thromb. Haemost. 119, 1539–1545 (2019).
Lebozec, K., Jandrot-Perrus, M., Avenard, G., Favre-Bulle, O. & Billiald, P. Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks. MAbs 9, 945–958 (2017).
Voors-Pette, C. et al. Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler. Thromb. Vasc. Biol. 39, 956–964 (2019).
Bergmeier, W., Chauhan, A. K. & Wagner, D. D. Glycoprotein Ibα and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb. Haemost. 99, 264–270 (2008).
Denorme, F. & De Meyer, S. F. The VWF-GPIb axis in ischaemic stroke: lessons from animal models. Thromb. Haemost. 116, 597–604 (2016).
Kremer Hovinga, J. A. et al. Thrombotic thrombocytopenic purpura. Nat. Rev. Dis. Primers 3, 17020 (2017).
Mikhail, S., Aldin, E. S., Streiff, M. & Zeidan, A. An update on type 2B von Willebrand disease. Expert. Rev. Hematol. 7, 217–231 (2014).
Firbas, C., Siller-Matula, J. M. & Jilma, B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert. Rev. Cardiovasc. Ther. 8, 1689–1701 (2010).
Gilbert, J. C. et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116, 2678–2686 (2007).
Bartunek, J. et al. Novel antiplatelet agents: ALX-0081, a nanobody directed towards von Willebrand factor. J. Cardiovasc. Transl. Res. 6, 355–363 (2013).
Kageyama, S., Matsushita, J. & Yamamoto, H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur. J. Pharmacol. 443, 143–149 (2002).
Kageyama, S. et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler. Thromb. Vasc. Biol. 22, 187–192 (2002).
Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 380, 335–346 (2019).
Markus, H. S. et al. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke 42, 2149–2153 (2011).
Zheng, L. et al. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura. Blood Adv. 1, 75–83 (2016).
Li, T. T. et al. A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury. Br. J. Pharmacol. 172, 3904–3916 (2015).
Lei, X. et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb. Haemost. 111, 279–289 (2014).
Quach, M. E., Chen, W. & Li, R. Mechanisms of platelet clearance and translation to improve platelet storage. Blood 131, 1512–1521 (2018).
Gratacap, M. P. et al. Regulation and roles of PI3Kbeta, a major actor in platelet signaling and functions. Adv. Enzyme Regul. 51, 106–116 (2011).
Martin, V. et al. Deletion of the p110β isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 115, 2008–2013 (2010).
Nylander, S. et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J. Thromb. Haemost. 10, 2127–2136 (2012).
Zheng, Z. et al. Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922). Eur. J. Med. Chem. 122, 339–351 (2016).
Nylander, S., Wagberg, F., Andersson, M., Skarby, T. & Gustafsson, D. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man. J. Thromb. Haemost. 13, 1494–1502 (2015).
Bekendam, R. H. & Flaumenhaft, R. Inhibition of protein disulfide isomerase in thrombosis. Basic Clin. Pharmacol. Toxicol. 119, 42–48 (2016).
Jasuja, R. et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J. Clin. Invest. 122, 2104–2113 (2012).
Stopa, J. D. et al. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight 2, e89373 (2017).
Zwicker, J. I. et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight 4, 125851 (2019).
Schwarz, M. et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ. Res. 99, 25–33 (2006).
Hanjaya-Putra, D. et al. Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis. JCI Insight 3, 99329 (2018).
Shen, B. et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature 503, 131–135 (2013).
Ikei, K. N. et al. Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation. J. Lipid Res. 53, 2546–2559 (2012).
Yeung, J. et al. 12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity. Thromb. Haemost. 110, 569–581 (2013).
Yeung, J. et al. Platelet 12-LOX is essential for FcgγRIIa-mediated platelet activation. Blood 124, 2271–2279 (2014).
Adili, R. et al. First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis. Arterioscler. Thromb. Vasc. Biol. 37, 1828–1839 (2017).
Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075–13080 (2010).
Brown, J. R. et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br. J. Haematol. 184, 558–569 (2019).
Busygina, K. et al. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. Blood 131, 2605–2616 (2018).
Giugliano, R. P. et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J. Am. Coll. Cardiol. 49, 2398–2407 (2007).
Vincent, J. L., Artigas, A., Petersen, L. C. & Meyer, C. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Crit. Care Med. 37, 1874–1880 (2009).
Wheeler, A. P. & Gailani, D. The intrinsic pathway of coagulation as a target for antithrombotic therapy. Hematol. Oncol. Clin. North Am. 30, 1099–1114 (2016).
Nickel, K. F., Long, A. T., Fuchs, T. A., Butler, L. M. & Renne, T. Factor XII as a therapeutic target in thromboembolic and inflammatory diseases. Arterioscler. Thromb. Vasc. Biol. 37, 13–20 (2017).
Weitz, J. I. & Fredenburgh, J. C. Platelet polyphosphate: the long and the short of it. Blood 129, 1574–1575 (2017).
Kenne, E. & Renne, T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug. Discov. Today 19, 1459–1464 (2014).
Verhamme, P. et al. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin. Ther. 32, 1205–1220 (2010).
Verhamme, P. et al. Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. J. Thromb. Haemost. 9, 664–671 (2011).
Eriksson, B. I. et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J. Thromb. Haemost. 6, 457–463 (2008).
Toomey, J. R. et al. Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis. Thromb. Res. 100, 73–79 (2000).
Toomey, J. R. et al. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke 33, 578–585 (2002).
Benincosa, L. J. et al. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 292, 810–816 (2000).
Chow, F. S. et al. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin. Pharmacol. Ther. 71, 235–245 (2002).
Dyke, C. K. et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114, 2490–2497 (2006).
Povsic, T. J. et al. A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur. Heart J. 34, 2481–2489 (2013).
Lincoff, A. M. et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet 387, 349–356 (2016).
Povsic, T. J. et al. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J. Allergy Clin. Immunol. 138, 1712–1715 (2016).
Weitz, J. I. & Harenberg, J. New developments in anticoagulants: past, present and future. Thromb. Haemost. 117, 1283–1288 (2017).
Weitz, J. I. & Fredenburgh, J. C. 2017 scientific sessions sol sherry distinguished lecture in thrombosis: factor xi as a target for new anticoagulants. Arterioscler. Thromb. Vasc. Biol. 38, 304–310 (2018).
Younis, H. S. et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood 119, 2401–2408 (2012).
Buller, H. R. et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. 372, 232–240 (2015). The trial shows that reducing levels of FXI using an antisense oligonucleotide is associated with reduced venous thrombosis in patients undergoing total knee arthroplasty without increasing bleeding.
Gomez-Outes, A., Garcia-Fuentes, M. & Suarez-Gea, M. L. Discovery methods of coagulation-inhibiting drugs. Expert. Opin. Drug. Discov. 12, 1195–1205 (2017).
Weitz, J. I. et al. Effect of Osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty. JAMA 323, 130–139 (2020).
Koch, A. W. et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood 133, 1507–1516 (2019).
Cheng, Q. et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 116, 3981–3989 (2010).
Lorentz, C. U. et al. Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial. Arterioscler. Thromb. Vasc. Biol. 39, 799–809 (2019).
Lakbakbi, S. et al. Tissue factor expressed by adherent cells contributes to hemodialysis-membrane thrombogenicity. Thromb. Res. 144, 218–223 (2016).
Bjorkqvist, J. et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J. Clin. Invest. 125, 3132–3146 (2015).
Jain, S. et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc. Natl Acad. Sci. USA 109, 12938–12943 (2012).
Travers, R. J., Shenoi, R. A., Kalathottukaren, M. T., Kizhakkedathu, J. N. & Morrissey, J. H. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 124, 3183–3190 (2014).
von Bruhl, M. L. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J. Exp. Med. 209, 819–835 (2012).
Brill, A. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J. Thromb. Haemost. 10, 136–144 (2012).
Leal, A. C. et al. Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci. Rep. 7, 6438 (2017).
Hisada, Y. et al. Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. Haematologica 105, 218–225 (2020).
Davis, J. C. Jr. et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8, 68–76 (1999).
Konigsbrugge, O. & Ay, C. Atrial fibrillation in patients with end-stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation. Res. Pract. Thromb. Haemost. 3, 578–588 (2019).
Dentali, F. et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113, 5617–5623 (2009).
Stone, G. W. et al. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364, 226–235 (2011).
Weber, W. et al. Noninvasive follow-up of GDC-treated saccular aneurysms by MR angiography. Eur. Radiol. 11, 1792–1797 (2001).
Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).
Brighton, T. A. et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N. Engl. J. Med. 367, 1979–1987 (2012).
Becattini, C. et al. Aspirin for preventing the recurrence of venous thromboembolism. N. Engl. J. Med. 366, 1959–1967 (2012).
Marik, P. E. & Cavallazzi, R. Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PLoS One 10, e0143252 (2015).
Weitz, J. I. et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N. Engl. J. Med. 376, 1211–1222 (2017).
Elwood, P. C. et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med. J. 1, 436–440 (1974).
Janzon, L. et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med. 227, 301–308 (1990).
Pettersen, A. A., Arnesen, H., Opstad, T. B. & Seljeflot, I. The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thromb. J. 9, 4 (2011).
Montalescot, G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723–731 (2009).
Bonaca, M. P., Braunwald, E. & Sabatine, M. S. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 373, 1271–1275 (2015).
Vranckx, P. et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392, 940–949 (2018).
Coller, B. S. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb. Haemost. 86, 427–443 (2001).
Bennett, J. S. Structure and function of the platelet integrin αIIbβ3. J. Clin. Invest. 115, 3363–3369 (2005).
Chew, D. P., Bhatt, D. L. & Topol, E. J. Oral glycoprotein IIb/IIIa inhibitors: why don’t they work? Am. J. Cardiovasc. Drugs 1, 421–428 (2001).
Cox, D. Oral GPIIb/IIIa antagonists: what went wrong? Curr. Pharm. Des. 10, 1587–1596 (2004).
Kahn, M. L. et al. A dual thrombin receptor system for platelet activation. Nature 394, 690–694 (1998).
Franchi, F., Rollini, F., Park, Y. & Angiolillo, D. J. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. Future Cardiol. 11, 547–564 (2015).
O’Donoghue, M. L. et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation 123, 1843–1853 (2011).
Wiviott, S. D. et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation 123, 1854–1863 (2011).
Goto, S. et al. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur. Heart J. 31, 2601–2613 (2010).
Kernan, W. N. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45, 2160–2236 (2014).
Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86 (2002).
Hemker, H. C. A century of heparin: past, present and future. J. Thromb. Haemost. 14, 2329–2338 (2016).
Lim, G. B. Milestone 1: discovery and purification of heparin. Nat. Rev. Cardiol. https://doi.org/10.1038/nrcardio.2017.171 (2017).
Best, C. H. Heparin and thrombosis. Br. Med. J. 2, 977–981 (1938).
Best, C. H., Cowan, C. & Maclean, D. L. Heparin and the formation of white thrombi. Science 85, 338–339 (1937).
Walenga, J. M. et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert. Opin. Investig. Drugs 11, 397–407 (2002).
Garcia, D. A., Baglin, T. P., Weitz, J. I. & Samama, M. M. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (Suppl. 2), e24–e43 (2012).
Lee, S. et al. Scientific considerations in the review and approval of generic enoxaparin in the United States. Nat. Biotechnol. 31, 220–226 (2013).
Wienbergen, H. & Zeymer, U. Management of acute coronary syndromes with fondaparinux. Vasc. Health Risk Manag. 3, 321–329 (2007).
Arepally, G. M. Heparin-induced thrombocytopenia. Blood 129, 2864–2872 (2017).
Nutescu, E. A., Burnett, A., Fanikos, J., Spinler, S. & Wittkowsky, A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J. Thromb. Thrombolysis 41, 15–31 (2016).
Barrowcliffe, T. W., Mulloy, B., Johnson, E. A. & Thomas, D. P. The anticoagulant activity of heparin: measurement and relationship to chemical structure. J. Pharm. Biomed. Anal. 7, 217–226 (1989).
Schroeder, M. et al. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Anal. Bioanal. Chem. 399, 763–771 (2011).
Link, K. P. The discovery of dicumarol and its sequels. Circulation 19, 97–107 (1959).
Pirmohamed, M. Warfarin: almost 60 years old and still causing problems. Br. J. Clin. Pharmacol. 62, 509–511 (2006).
Presnell, S. R. & Stafford, D. W. The vitamin K-dependent carboxylase. Thromb. Haemost. 87, 937–946 (2002).
Tie, J. K. & Stafford, D. W. Structural and functional insights into enzymes of the vitamin K cycle. J. Thromb. Haemost. 14, 236–247 (2016).
Moualla, H. & Garcia, D. Vitamin K antagonists–current concepts and challenges. Thromb. Res. 128, 210–215 (2011).
Hanley, J. P. Warfarin reversal. J. Clin. Pathol. 57, 1132–1139 (2004).
Gage, B. F. & Lesko, L. J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 25, 45–51 (2008).
Futatani, T., Watanabe, C., Baba, Y., Tsukada, S. & Ochs, H. D. Bruton’s tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br. J. Haematol. 114, 141–149 (2001).
Bain, J. & Meyer, A. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia. Am. J. Health Syst. Pharm. 72 (Suppl. 2), 104–109 (2015).
Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009). The trial shows that, in patients with atrial fibrillation, dabigatran was associated with similar rates of stroke and systemic embolism to those associated with warfarin but with lower rates of major haemorrhage.
Pollack, C. V. Jr. et al. Idarucizumab for dabigatran reversal. N. Engl. J. Med. 373, 511–520 (2015).
Pollack, C. V. Jr. et al. Idarucizumab for dabigatran reversal – full cohort analysis. N. Engl. J. Med. 377, 431–441 (2017).
Hutcherson, T. C., Cieri-Hutcherson, N. E. & Bhatt, R. Evidence for idarucizumab (Praxbind) in the reversal of the direct thrombin inhibitor dabigatran: review following the RE-VERSE AD full cohort analysis. P. T. 42, 692–698 (2017).
Pour-Ghaz, I. et al. Transcatheter aortic valve replacement with a focus on transcarotid: a review of the current literature. Ann. Transl. Med. 7, 420 (2019).
Joppa, S. A. et al. A practical review of the emerging direct anticoagulants, laboratory monitoring, and reversal agents. J. Clin. Med. 7, E29 (2018).
Lu, G. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19, 446–451 (2013).
Connolly, S. J. et al. Full study report of andexanet alfa for bleeding associated with factor Xa Inhibitors. N. Engl. J. Med. 380, 1326–1335 (2019).
Heo, Y. A. Andexanet Alfa: first global approval. Drugs 78, 1049–1055 (2018).
Ruff, C. T. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383, 955–962 (2014).
The authors would like to thank Cihan Ay, Jonathan Erlich, Steven Grover, Raj Kasthuri, Carolyn Mackman and Dougald Monroe III for helpful comments and Yohei Hisada for help with preparing the manuscript.
G.A.S. and W.B. have no competing interests. N.M. has a grant from Bayer and is a consultant for Bayer. J.I.W. is a consultant for Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Bayer, Janssen, Boehringer Ingelheim, IONIS Pharmaceuticals, Merck, Portola, Perosphere, Servier, Anthos and Tetherex.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Cardiovascular disease
Disorders of the heart and blood vessels.
Small enucleate cells in the blood involved in clotting.
Arrest of bleeding after damage to a blood vessel.
- Antisense oligonucleotides
(ASOs). Antisense oligonucleotides reduce protein expression by binding to mRNA and increasing its degradation.
About this article
Cite this article
Mackman, N., Bergmeier, W., Stouffer, G.A. et al. Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov 19, 333–352 (2020). https://doi.org/10.1038/s41573-020-0061-0
This article is cited by
Signal Transduction and Targeted Therapy (2022)
Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation
Nature Cardiovascular Research (2022)
New insights into geraniol’s antihemolytic, anti-inflammatory, antioxidant, and anticoagulant potentials using a combined biological and in silico screening strategy
Journal of Nuclear Cardiology (2022)
In vitro models (2022)